NASDAQ · Biotechnology

Spyre Therapeutics, Inc. (SYRE) Stock

$85.69 +7.25% NASDAQ: SYRE Healthcare

Valuation

MetricValue
Price$85.69
Market Cap$7.44B
P/E Ratio-47.79
P/B Ratio7.17
P/S Ratio89.43
EPS (TTM)$-1.98
52-Week High$110.18
52-Week Low$15.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-24.32%
ROA-15.25%
ROCE-18.14%
Gross Margin0.00%
Operating Margin-2.56%
Net Margin-197.71%
Debt/Equity0.00
Current Ratio13.19

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$2.0M$1.0M$0$0
Operating Profit$-66.0M$-85.0M$-242.0M$-209.0M$-210.0M
Net Profit$-66.0M$-84.0M$-339.0M$-208.0M$-155.0M
EPS$-25.02$-24.86$-46.15$-3.18$-1.98
Op Margin-350.3%-3640.2%-27348.0%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$110.0M$71.0M$342.0M$608.0M$778.0M
Total Liabilities$26.0M$21.0M$158.0M$91.0M$63.0M
Cash$15.0M$35.0M$189.0M$89.0M$86.0M
Borrowings$5.0M$5.0M$0$0$0

Latest News

Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating MT Newswires · Jul 13, 2026 Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing MT Newswires · Jul 6, 2026 Spyre Therapeutics Announces Grants of Inducement Awards GlobeNewswire · Jul 2, 2026 Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts Zacks · Jun 29, 2026 Spyre Therapeutics Insider Sold Shares Worth $1,307,000, According to a Recent SEC Filing MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-54.0M$-80.0M$-100.0M$-157.0M$-169.0M
Investing Cash Flow$-23.0M$57.0M$-108.0M$-353.0M$-143.0M
Financing Cash Flow$2.0M$0$-5.0M$6.0M$-5.0M
Net Cash Flow$-75.0M$19.0M$153.0M$-100.0M$-4.0M
Free Cash Flow$-54.0M$-80.0M$-100.0M$-157.0M$-169.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.94
EV / EBITDA-42.74
FCF Yield-2.58%
Quick Ratio18.53
Interest Coverage0.00
Return 1Y483.17%
Return 3Y724.69%
Return 5Y-57.37%

Ownership

Insiders Held5.86%
Institutions Held93.35%
Institutions Float Held99.16%
Institutional HolderSharesReport Date
FMR, LLC11,781,0242026-03-31
Blackrock Inc.5,521,2212026-03-31
RTW Investments LP4,171,9962026-03-31
Fairmount Funds Management LLC4,018,1012026-03-31
Perceptive Advisors Llc3,783,2252026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is led by CEO Cameron Turtle, employs 112 people, headquartered in Waltham, US, publicly traded since 2016.

Spyre Therapeutics, Inc. (SYRE) stock trades at $85.69 with a market capitalization of $7.44B. The stock is valued at a price-to-earnings (P/E) ratio of -47.79, price-to-book of 7.17, price-to-sales of 89.43. Over the past 52 weeks the stock has ranged between $15.86 and $110.18, and currently trades 22.2% below its 52-week high.

On profitability, Spyre Therapeutics, Inc. generates a return on equity (ROE) of -24.32%, return on capital employed of -18.14%, an operating margin of -2.56%, a net profit margin of -197.71%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides